Overview

This recorded webinar highlights how AstraZeneca leveraged the unique capabilities of the Intellicyt iQue® Screener platform to run a 500 thousand compound cell viability screen and a target specific bead-based assay involving three of the major risk genes/factors associated with Amyotrophic Lateral Sclerosis (ALS) to identify novel inhibitors of target-induced toxicity.


Register to watch on demand

Request More Information

What other areas are you interested in? (select all that apply)

Register to watch the on-demand webinar